Kyorin Pharmaceutical Co. Ltd. has out-licensed its preclinical candidate, KRP-M223, and its back-up compounds to Novartis Pharma AG in a deal worth up to $777.5 million. Under the terms, Novartis ...

The U.K has released a huge repository of children’s genomic data after sequencing blood samples from three large cohorts recruited at birth and followed across three decades. The power of the data is ...

Japan’s Kyorin Pharmaceutical has entered into a global license agreement with Swiss pharma giant Novartis relating to ...

Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...

M223, a preclinical drug for inflammatory diseases, with potential milestone payments of $777.5M plus royalties.

After Novartis and Roche grew their sales last year, the Swiss pharma giants are handing their CEOs larger compensation packages for 2024. At Novartis, CEO Vas Narasimhan’s overall 2024 pay ...

Under this agreement, KYORIN obtains an option for the license of the right to develop and commercialize CYR-064 in Japan and will pay an option fee to Cyrano. Upon exercising the option and ...

DELRAY BEACH, Fla., Feb. 18, 2025 /PRNewswire/ -- Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, announced ...

Novartis has set a high bar for any potential obesity-treatment acquisition as it scans the market for deals to fill its drug pipeline and power sales growth into the 2030s, its chief executive ...